세계의 다낭성 신장질환 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 유형별, 치료 유형별, 최종 사용자별, 지역별, 경쟁별(2020-2030년)
Polycystic Kidney Disease Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Treatment Type, By End User, By Region and Competition, 2020-2030F
상품코드:1728154
리서치사:TechSci Research
발행일:2025년 05월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 다낭성 신장질환(PKD) 시장은 2024년 5억 239만 달러로 평가되었고, 2030년에는 7억 5,869만 달러에 이를 것으로 예측되며, 예측 기간 동안 CAGR 7.11%로 성장할 전망입니다.
PKD는 신장에 체액으로 채워진 낭종이 성장하여 신장이 점차 커지고 결국 신부전으로 이어지는 유전적 질환입니다. 상염색체 우성 및 열성 형태의 PKD의 전 세계적인 유병률 증가, 진단 능력 향상, 연구 투자 증가로 인해 시장 확대가 추진되고 있습니다. 정밀 의학의 발전으로 개인의 유전자 프로필에 기반한 보다 표적화된 치료 접근법이 가능해졌습니다. 환자 인구의 증가와 함께 의료 전문가들의 인식이 높아지고 조기 발견을 위한 유전자 검사가 통합되면서 효과적인 치료 옵션에 대한 수요가 증가하고 있습니다. 제약 회사와 연구 기관은 질병 진행을 지연시키고 환자 치료 결과를 개선하기 위한 혁신적인 개입 개발에 점점 더 집중하고 있으며, 이는 시장 성장을 촉진하고 있습니다.
시장 개요
예측 기간
2026-2030년
시장 규모(2024년)
5억239만 달러
시장 규모(2030년)
7억 5,869만 달러
CAGR(2025-2030년)
7.11%
급성장 부문
상염색체 우성 다낭성 신장 질환(ADPKD)
최대 시장
북미
시장 성장 촉진요인
다낭성 신장질환(PKD)의 유병률 증가
주요 시장 과제
높은 치료 비용
주요 시장 동향
유전자 연구의 발전
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 세계의 다낭성 신장질환 시장 전망
시장 규모와 예측
금액별
시장 점유율 및 예측
유형별(상염색체 우성 다낭성 신장 질환(ADPKD), 상염색체 열성 다낭성 신장 질환(ARPKD), 기타)
치료 유형별(진단, 약물 치료)
최종 사용자별(병원 및 진료소, 외래 진료 센터, 기타)
지역별
기업별(2024년)
시장 맵
유형별
치료 유형별
최종 사용자별
지역별
제5장 아시아태평양의 다낭성 신장질환 시장 전망
시장 규모와 예측
금액별
시장 점유율 및 예측
유형별
치료유형별
최종 사용자별
국가별
아시아태평양 : 국가별 분석
중국
인도
호주
일본
한국
제6장 유럽의 다낭성 신장질환 시장 전망
시장 규모와 예측
시장 점유율 및 예측
유럽 : 국가별 분석
프랑스
독일
스페인
이탈리아
영국
제7장 북미의 다낭성 신장질환 시장 전망
시장 규모와 예측
시장 점유율 및 예측
북미 : 국가별 분석
미국
멕시코
캐나다
제8장 남미의 다낭성 신장질환 시장 전망
시장 규모와 예측
시장 점유율 및 예측
남미 : 국가별 분석
브라질
아르헨티나
콜롬비아
제9장 중동 및 아프리카의 다낭성 신장질환 시장 전망
시장 규모와 예측
시장 점유율 및 예측
중동 및 아프리카 : 국가별 분석
남아프리카
사우디아라비아
아랍에미리트(UAE)
제10장 시장 역학
성장 촉진요인
과제
제11장 시장 동향과 발전
최근 동향
제품 출시
합병과 인수
제12장 세계의 철 결핍성 빈혈: SWOT 분석
제13장 Porter's Five Forces 분석
업계 내 경쟁
신규 진입의 가능성
공급자의 힘
고객의 힘
대체품의 위협
제14장 경쟁 구도
Otsuka Pharmaceuticals
Camber Pharmaceuticals
Apotex Corp
Ascend Laboratories
Par Pharmaceuticals
Teva Pharmaceutical Industries
Merck KGA
Accord Healthcare
Pfizer Inc.
PD-Rx Pharmaceuticals, Inc
제15장 전략적 제안
제16장 기업 소개와 면책사항
HBR
영문 목차
영문목차
The Global Polycystic Kidney Disease (PKD) Market was valued at USD 502.39 million in 2024 and is projected to reach USD 758.69 million by 2030, growing at a CAGR of 7.11% during the forecast period. PKD is a genetic condition characterized by the growth of fluid-filled cysts in the kidneys, leading to progressive kidney enlargement and eventual renal failure. Market expansion is being propelled by a rising global prevalence of both autosomal dominant and recessive forms of PKD, improved diagnostic capabilities, and increased research investment. Advancements in precision medicine are enabling more targeted therapeutic approaches based on individual genetic profiles. The growing patient population, combined with heightened awareness among healthcare professionals and the integration of genetic screening for early detection, has stimulated demand for effective treatment options. Pharmaceutical companies and research institutions are increasingly focused on developing innovative interventions to delay disease progression and enhance patient outcomes, thereby fueling market growth.
Increasing Prevalence of Polycystic Kidney Disease (PKD)
The rising incidence of PKD worldwide is a major growth catalyst for the market. As a hereditary condition, PKD has seen growing diagnosis rates due to enhanced screening and genetic testing. Autosomal dominant PKD (ADPKD) affects approximately 1 in every 400 to 1,000 people, while autosomal recessive PKD (ARPKD) occurs in 1 in 20,000 to 40,000 individuals. With healthcare systems adopting more robust diagnostic practices, particularly among individuals with a family history of the disease, the patient pool is expanding. Increased awareness among clinicians and the general public has led to earlier detection and intervention, promoting demand for both supportive and disease-modifying therapies. As the affected population grows, pharmaceutical investment in PKD-focused research and treatment innovation is also accelerating.
Key Market Challenges
High Treatment Costs
The high cost associated with PKD treatment continues to hinder broader access and adoption of advanced therapies. Management of PKD often requires lifelong monitoring, imaging, nephrology consultations, and eventually renal replacement therapies such as dialysis or kidney transplantation in advanced cases. Limited availability of approved and cost-effective medications further compounds the financial burden on patients. Targeted drugs that are in clinical development or recently approved tend to be expensive, making them inaccessible to many, particularly in low-resource settings. Additionally, the long-term costs of managing disease progression and complications place pressure on both patients and healthcare systems, posing a substantial challenge to the market's growth and equitable treatment access.
Key Market Trends
Advancements in Genetic Research
Ongoing progress in genetic research is significantly influencing the PKD treatment landscape. Identification of mutations in genes such as PKD1 and PKD2 has facilitated the development of personalized treatment strategies and innovative therapies targeting the molecular mechanisms driving cyst formation. Gene-editing technologies and pharmacogenomics are enabling the design of more effective and potentially curative interventions. Furthermore, the discovery of reliable biomarkers is supporting early diagnosis, disease monitoring, and patient stratification for clinical trials. These advancements are streamlining drug development and paving the way for precision medicine in PKD care. Collaborations among geneticists, pharmaceutical companies, and advocacy groups are accelerating these efforts, increasing the pace at which research translates into clinical practice and market offerings.
Key Market Players
Otsuka Pharmaceuticals
Camber Pharmaceuticals
Apotex Corp
Ascend Laboratories
Par Pharmaceuticals
Teva Pharmaceutical Industries
Merck KGA
Accord Healthcare
Pfizer Inc.
PD-Rx Pharmaceuticals, Inc
Report Scope:
In this report, the Global Polycystic Kidney Disease Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Global Polycystic Kidney Disease Market, By Treatment Type:
Diagnosis
Drug/Therapy
Global Polycystic Kidney Disease Market, By End User:
Hospitals & Clinics
Ambulatory Care Centers
Others
Global Polycystic Kidney Disease Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Polycystic Kidney Disease Market.
Available Customizations:
Global Polycystic Kidney Disease Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Global Polycystic Kidney Disease Market Outlook
4.1. Market Size & Forecast
4.1.1. By Value
4.2. Market Share & Forecast
4.2.1. By Type (Autosomal dominant polycystic kidney disease (ADPKD), Autosomal recessive polycystic kidney disease (ARPKD), Others)
4.2.2. By Treatment Type (Diagnosis, Drug/Therapy)
4.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
4.2.4. By Region
4.2.5. By Company (2024)
4.3. Market Map
4.3.1. By Type
4.3.2. By Treatment Type
4.3.3. By End User
4.3.4. By Region
5. Asia Pacific Polycystic Kidney Disease Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type
5.2.2. By Treatment Type
5.2.3. By End User
5.2.4. By Country
5.3. Asia Pacific: Country Analysis
5.3.1. China Polycystic Kidney Disease Market Outlook
5.3.1.1. Market Size & Forecast
5.3.1.1.1. By Value
5.3.1.2. Market Share & Forecast
5.3.1.2.1. By Type
5.3.1.2.2. By Treatment Type
5.3.1.2.3. By End User
5.3.2. India Polycystic Kidney Disease Market Outlook
5.3.2.1. Market Size & Forecast
5.3.2.1.1. By Value
5.3.2.2. Market Share & Forecast
5.3.2.2.1. By Type
5.3.2.2.2. By Treatment Type
5.3.2.2.3. By End User
5.3.3. Australia Polycystic Kidney Disease Market Outlook
5.3.3.1. Market Size & Forecast
5.3.3.1.1. By Value
5.3.3.2. Market Share & Forecast
5.3.3.2.1. By Type
5.3.3.2.2. By Treatment Type
5.3.3.2.3. By End User
5.3.4. Japan Polycystic Kidney Disease Market Outlook
5.3.4.1. Market Size & Forecast
5.3.4.1.1. By Value
5.3.4.2. Market Share & Forecast
5.3.4.2.1. By Type
5.3.4.2.2. By Treatment Type
5.3.4.2.3. By End User
5.3.5. South Korea Polycystic Kidney Disease Market Outlook
5.3.5.1. Market Size & Forecast
5.3.5.1.1. By Value
5.3.5.2. Market Share & Forecast
5.3.5.2.1. By Type
5.3.5.2.2. By Treatment Type
5.3.5.2.3. By End User
6. Europe Polycystic Kidney Disease Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Treatment Type
6.2.3. By End User
6.2.4. By Country
6.3. Europe: Country Analysis
6.3.1. France Polycystic Kidney Disease Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Treatment Type
6.3.1.2.3. By End User
6.3.2. Germany Polycystic Kidney Disease Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Treatment Type
6.3.2.2.3. By End User
6.3.3. Spain Polycystic Kidney Disease Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Treatment Type
6.3.3.2.3. By End User
6.3.4. Italy Polycystic Kidney Disease Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Type
6.3.4.2.2. By Treatment Type
6.3.4.2.3. By End User
6.3.5. United Kingdom Polycystic Kidney Disease Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Type
6.3.5.2.2. By Treatment Type
6.3.5.2.3. By End User
7. North America Polycystic Kidney Disease Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Treatment Type
7.2.3. By End User
7.2.4. By Country
7.3. North America: Country Analysis
7.3.1. United States Polycystic Kidney Disease Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Treatment Type
7.3.1.2.3. By End User
7.3.2. Mexico Polycystic Kidney Disease Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Treatment Type
7.3.2.2.3. By End User
7.3.3. Canada Polycystic Kidney Disease Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Treatment Type
7.3.3.2.3. By End User
8. South America Polycystic Kidney Disease Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Treatment Type
8.2.3. By End User
8.2.4. By Country
8.3. South America: Country Analysis
8.3.1. Brazil Polycystic Kidney Disease Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Treatment Type
8.3.1.2.3. By End User
8.3.2. Argentina Polycystic Kidney Disease Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Treatment Type
8.3.2.2.3. By End User
8.3.3. Colombia Polycystic Kidney Disease Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Treatment Type
8.3.3.2.3. By End User
9. Middle East and Africa Polycystic Kidney Disease Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Treatment Type
9.2.3. By End User
9.2.4. By Country
9.3. MEA: Country Analysis
9.3.1. South Africa Polycystic Kidney Disease Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Treatment Type
9.3.1.2.3. By End User
9.3.2. Saudi Arabia Polycystic Kidney Disease Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Treatment Type
9.3.2.2.3. By End User
9.3.3. UAE Polycystic Kidney Disease Market Outlook
